Is pulmonary vascular disease reversible with PPAR ɣ agonists?

Area of Science:

• Cardiovascular Research
• Pulmonary Hypertension
• Molecular Medicine

Background:

• Severe pulmonary arterial hypertension (PAH) involves angio-obliterative changes, leading to high morbidity and reduced survival.
• Current treatments for angio-obliterative PAH are palliative (e.g., sildenafil, Bosentan), with lung transplantation being the only definitive but limited option.

Purpose of the Study:

• To investigate the potential of peroxisome proliferator-activated receptor gamma (PPARγ) agonists in reversing severe pulmonary angio-obliterative changes.
• To explore if PPARγ agonists can promote microvascular regeneration as an alternative to lung transplantation.

Main Methods:

• Focus on the expression of PPARs, particularly the gamma isoform, in pulmonary artery cells and endothelial progenitor cells.
• Leverage existing research on PPARγ agonists' role in reversing vascular remodeling in other diseases.
• Hypothesize the multifaceted effects of PPARγ activation on PAH pathobiological pathways.

Main Results:

• PPARγ agonists have demonstrated efficacy in reversing vascular remodeling in preclinical models of atherosclerosis.
• PPARγ activation influences multiple pathways critical to the development of PAH.
• Experimental evidence suggests a broad impact on the pathobiology of PAH.

Conclusions:

• PPARγ agonists may hold significant potential for reversing angio-obliterative changes in severe PAH.
• Microvascular regeneration induced by PPARγ agonists could offer a novel therapeutic strategy, potentially reducing the need for lung transplantation.